Belantamab mafodotin-blmf
Belantamab mafodotin-blmf (pronunciation: bel-an-TAM-ab maf-oh-DOH-tin) is a monoclonal antibody-drug conjugate used for the treatment of multiple myeloma. It is marketed under the brand name Blenrep by GlaxoSmithKline.
Etymology
The name "Belantamab mafodotin-blmf" is derived from its components: "Bel" for the monoclonal antibody belantamab, "maf" for the drug mafodotin, and "blmf" as a unique identifier.
Usage
Belantamab mafodotin-blmf is used for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Mechanism of Action
Belantamab mafodotin-blmf works by binding to the BCMA (B-cell maturation antigen) on the surface of multiple myeloma cells, and delivering the cytotoxic drug mafodotin directly to the cells.
Side Effects
Common side effects of Belantamab mafodotin-blmf include keratopathy, blurred vision, dry eyes, and decreased visual acuity.
Related Terms
- Monoclonal antibody
- Drug conjugate
- Multiple myeloma
- BCMA (B-cell maturation antigen)
- Anti-CD38 monoclonal antibody
- Proteasome inhibitor
- Immunomodulatory agent
- Keratopathy
External links
- Medical encyclopedia article on Belantamab mafodotin-blmf
- Wikipedia's article - Belantamab mafodotin-blmf
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski